Skip to main content

Articles

Page 34 of 39

  1. The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanomas development and progression, such as BRAF, CKIT an...

    Authors: Giovanni Ponti, Aldo Tomasi and Giovanni Pellacani
    Citation: Journal of Hematology & Oncology 2012 5:60
  2. Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma ris...

    Authors: Kari Hemminki, Xiangdong Liu, Asta Försti, Jianguang Ji, Jan Sundquist and Kristina Sundquist
    Citation: Journal of Hematology & Oncology 2012 5:59
  3. Colorectal Cancer (CRC) is one of the leading causes of death worldwide. Numerous cellular events, including deregulated expression of microRNAs (miRNAs), specifically the family of miR-34 consisting of miR-34...

    Authors: Sanchita Roy, Edi Levi, Adhip PN Majumdar and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2012 5:58
  4. Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM...

    Authors: Angela M Sosin, Angelika M Burger, Aisha Siddiqi, Judith Abrams, Ramzi M Mohammad and Ayad M Al-Katib
    Citation: Journal of Hematology & Oncology 2012 5:57
  5. Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF ...

    Authors: Bruno Vincenzi, Andrea Napolitano, Alice Zoccoli, Michele Iuliani, Francesco Pantano, Nicola Papapietro, Vincenzo Denaro, Daniele Santini and Giuseppe Tonini
    Citation: Journal of Hematology & Oncology 2012 5:56
  6. Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This...

    Authors: Kang Lu and Xin Wang
    Citation: Journal of Hematology & Oncology 2012 5:55
  7. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin Lymphoma comprising of greater than 30% of adult non-Hodgkin Lymphomas. DLBCL represents a diverse set of lymphomas, defined as diff...

    Authors: Carlos A Tirado, Weina Chen, Rolando García, Kelly A Kohlman and Nagesh Rao
    Citation: Journal of Hematology & Oncology 2012 5:54
  8. Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Si...

    Authors: Sara Galimberti, Francesca Guerrini, Flavia Salvi, Iacopo Petrini, Daniela Gioia, Emanuela Messa, Giuseppe A Palumbo, Daniela Cilloni, Mario Petrini and Alessandro Levis
    Citation: Journal of Hematology & Oncology 2012 5:53
  9. Epidermal growth factor receptor gene copy number (EGFR GCN) has been heavily investigated as a potential predictive biomarker for the treatment of metastatic colorectal cancer (mCRC) with anti-EGFR monoclonal an...

    Authors: Zu-Yao Yang, Wei-Xi Shen, Xue-Feng Hu, Da-Yong Zheng, Xin-Yin Wu, Ya-Fang Huang, Jin-Zhang Chen, Chen Mao and Jin-Ling Tang
    Citation: Journal of Hematology & Oncology 2012 5:52
  10. The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to ritux...

    Authors: Xuan Jin, Huirong Ding, Ning Ding, Zhiying Fu, Yuqin Song and Jun Zhu
    Citation: Journal of Hematology & Oncology 2012 5:51
  11. The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.

    Authors: Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok Hyun Yoon, Ho-Jin Shin, Yeung-Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung-Soon Jang, Won-Sik Lee, Hwe-Won Lee…
    Citation: Journal of Hematology & Oncology 2012 5:49
  12. The molecular pathogenesis underlying the primary myelofibrosis (PMF) progression to acute myeloid leukemia (AML) is still not well defined. The involvement of microRNA (miRNA) is actually helping to shed ligh...

    Authors: Francesco Albano, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Paola Casieri, Angela Minervini and Giorgina Specchia
    Citation: Journal of Hematology & Oncology 2012 5:48
  13. The mechanisms responsible for chemoresistance in patients with refractory classical Hodgkin lymphoma (CHL) are unknown. ATP-binding cassette (ABC) transporters confer multidrug resistance in various cancers and

    Authors: Wesley Greaves, Lianchun Xiao, Beatriz Sanchez-Espiridion, Kranthi Kunkalla, Kunal S Dave, Cynthia S Liang, Rajesh R Singh, Anas Younes, L Jeffrey Medeiros and Francisco Vega
    Citation: Journal of Hematology & Oncology 2012 5:47
  14. Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce...

    Authors: Li Xuan, Fen Huang, Zhiping Fan, Hongsheng Zhou, Xian Zhang, Guopan Yu, Yu Zhang, Can Liu, Jing Sun and Qifa Liu
    Citation: Journal of Hematology & Oncology 2012 5:46
  15. Although GATA1 is one of the most extensively studied haematopoietic transcription factors little is currently known about the physiological functions of its naturally occurring isoforms GATA1s and GATA1FL in hum...

    Authors: Christina Halsey, Marie Docherty, Mhairi McNeill, Derek Gilchrist, Michelle Le Brocq, Brenda Gibson and Gerard Graham
    Citation: Journal of Hematology & Oncology 2012 5:45
  16. Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including hig...

    Authors: Luana Fianchi, Marianna Criscuolo, Monia Lunghi, Gianluca Gaidano, Massimo Breccia, Alessandro Levis, Carlo Finelli, Valeria Santini, Pellegrino Musto, Esther N Oliva, Pietro Leoni, Antonietta Aloe Spiriti, Francesco D’Alò, Stefan Hohaus, Livio Pagano, Giuseppe Leone…
    Citation: Journal of Hematology & Oncology 2012 5:44
  17. Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome...

    Authors: Jasleen Randhawa, Alen Ostojic, Radovan Vrhovac, Ehab Atallah and Srdan Verstovsek
    Citation: Journal of Hematology & Oncology 2012 5:43
  18. Acute lymphoblastic leukemia (ALL) is the most frequently-occurring malignant neoplasm in children, but the pathogenesis of the disease remains unclear. In a microarray assay using samples from 100 children wi...

    Authors: Limin Zou, Han Zhang, Chaohao Du, Xiao Liu, Shanshan Zhu, Wei Zhang, Zhigang Li, Chao Gao, Xiaoxi Zhao, Mei Mei, Shilai Bao and Huyong Zheng
    Citation: Journal of Hematology & Oncology 2012 5:42
  19. This study was aimed to investigate the significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis (sHLH) patients. A total of 18 patients received 18F-FDG PET/CT scan at initial diagnosis. Al...

    Authors: Li-Juan Zhang, Ji Xu, Peng Liu, Chong-Yang Ding, Jian-Yong Li, Hong-Xia Qiu and Su-Jiang Zhang
    Citation: Journal of Hematology & Oncology 2012 5:40
  20. Gain-of-function mutations of tyrosine kinase FLT3 are frequently found in acute myeloid leukemia (AML). This has made FLT3 an important marker for disease diagnosis and a highly attractive target for therapeu...

    Authors: Yun Chen, Yao Guo, Jiayu Han, Wanting Tina Ho, Shibo Li, Xueqi Fu and Zhizhuang Joe Zhao
    Citation: Journal of Hematology & Oncology 2012 5:39
  21. Systemic anaplastic large cell lymphoma (S-ALCL) is a rare disease with a highly variable prognosis and no standard chemotherapy regimen. Anaplastic lymphoma kinase (ALK) has been reported as an important prog...

    Authors: Yan-Fang Wang, Yan-Li Yang, Zi-Fen Gao, Chun-Ju Zhou, Xylina Gregg, Yun-Fei Shi, Jing Wang, Xiao-Feng Yang and Xiao-Yan Ke
    Citation: Journal of Hematology & Oncology 2012 5:38
  22. Hepatocellular carcinoma (HCC) is one of the most common malignant tumors occurring mainly in patients with chronic liver disease. Detection of early HCC is critically important for treatment of these patients.

    Authors: Yantong Guo, Jingming Zhao, Jingtao Bi, Quan Wu, Xin Wang and Quanyou Lai
    Citation: Journal of Hematology & Oncology 2012 5:37
  23. Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Signific...

    Authors: Xuan Huang, Cindy H Chau and William D Figg
    Citation: Journal of Hematology & Oncology 2012 5:35
  24. Multiple immunotherapy approaches have improved adaptive anti-tumor immune responses in patients with early stage disease; however, results have been less dramatic when treating patients with late stage diseas...

    Authors: Jarrod D Predina, Veena Kapoor, Brendan F Judy, Guanjun Cheng, Zvi Gregory Fridlender, Steven M Albelda and Sunil Singhal
    Citation: Journal of Hematology & Oncology 2012 5:34
  25. Autologous stem cell transplantation (ASCT) is the gold standard therapy for suitable multiple myeloma (MM) patients after induction with high dose therapy. To date, the evidence of a reliable marker of progno...

    Authors: Cristina Guimarães, Rui Bergantim, Renata Ramalho, Nuno Couto, João T Guimarães and Fernanda Trigo
    Citation: Journal of Hematology & Oncology 2012 5:33
  26. Ribosomes are essential components of the protein translation machinery and are composed of more than 80 unique large and small ribosomal proteins. Recent studies show that in addition to their roles in protei...

    Authors: Niraj Shenoy, Rachel Kessel, Tushar D Bhagat, Sanchari Bhattacharyya, Yiting Yu, Christine Mcmahon and Amit Verma
    Citation: Journal of Hematology & Oncology 2012 5:32
  27. Contemporary advancements have had little impact on the treatment of gastric cancer (GC), the world’s second highest cause of cancer death. Agents targeting human epidermal growth factor receptor mediated path...

    Authors: Lian Liu, Ning Wu and Jin Li
    Citation: Journal of Hematology & Oncology 2012 5:31
  28. Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder of elderly people. Cardiac dysfunction is a marker of grim prognosis in MDS. We evaluated cardiac dysfunction of MDS patients with or...

    Authors: Cláudio César Monteiro de Castro, Carlos Bellini Gondim Gomes, Manoel Ricardo Alves Martins, Juliana Cordeiro de Sousa, Silvia MM Magalhaes and Ronald F Pinheiro
    Citation: Journal of Hematology & Oncology 2012 5:30
  29. Maintenance therapy with imatinib during the post-transplant period has been used for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been ...

    Authors: Huan Chen, Kai-yan Liu, Lan-ping Xu, Dai-hong Liu, Yu-hong Chen, Xiang-yu Zhao, Wei Han, Xiao-hui Zhang, Yu Wang, Yuan-yuan Zhang, Ya-zhen Qin, Yan-rong Liu and Xiao-jun Huang
    Citation: Journal of Hematology & Oncology 2012 5:29
  30. We have reported promising outcomes using a staged approach, in which bortezomib/thalidomide/dexamethasone was used only in 14 patients with suboptimal response to VAD (vincristine/adriamycin/dexamethasone) be...

    Authors: Chor Sang Chim, Albert Kwok Wai Lie, Eric Yuk Tat Chan, Herman Sung Yu Liu, Ching Wa Lau, Sze Fai Yip, Joycelyn Sim, Thomas Shek-Kong Wan, Edmond Shiu-Kwan Ma, Raymond Liang, Eric Tse and Yok-Lam Kwong
    Citation: Journal of Hematology & Oncology 2012 5:28
  31. Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to det...

    Authors: Adrien Chauchet, Anne-Sophie Michallet, Françoise Berger, Isabelle Bedgedjian, Eric Deconinck, Catherine Sebban, Daciana Antal, Hubert Orfeuvre, Bernadette Corront, Tony Petrella, Maya Hacini, Marie Bouteloup, Gilles Salles and Bertrand Coiffier
    Citation: Journal of Hematology & Oncology 2012 5:27
  32. MicroRNA have a central role in normal haematopoiesis and are deregulated in acute myeloid leukaemia (AML). The purpose of the study was to investigate by qRT-PCR the expression of miRNAs involved in myeloid d...

    Authors: Isabella Faraoni, Serena Laterza, Davide Ardiri, Claudia Ciardi, Francesco Fazi and Francesco Lo-Coco
    Citation: Journal of Hematology & Oncology 2012 5:26
  33. Chronic lymphocytic leukemia (CLL) is the rarest adult leukemia in Japan, whereas it is the most common leukemia in the Western world. Recent studies from the United States and Germany suggest a possible etiol...

    Authors: Masayuki Imajoh, Yumiko Hashida, Ayuko Taniguchi, Mikio Kamioka and Masanori Daibata
    Citation: Journal of Hematology & Oncology 2012 5:25
  34. Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in ...

    Authors: Salvia Jain, Jasmine Zain and Owen O’Connor
    Citation: Journal of Hematology & Oncology 2012 5:24
  35. The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating dasa...

    Authors: Naoto Takahashi, Masatomo Miura, Stuart A Scott, Takenori Niioka and Kenichi Sawada
    Citation: Journal of Hematology & Oncology 2012 5:23
  36. Although the importance of the hematopoietic transcription factor PU.1 in acute myeloid leukemia (AML) has been demonstrated, the expression of PU.1 in acute promyelocytic leukemia (APL) patient samples awaits...

    Authors: Xuehua Zhu, Hui Zhang, Maoxiang Qian, Xujie Zhao, Wentao Yang, Ping Wang, Ji Zhang and Kankan Wang
    Citation: Journal of Hematology & Oncology 2012 5:22
  37. The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomy...

    Authors: Gurpreet Lamba, Samir Ambrale, Byung Lee, Ridhi Gupta, Shamudheen M Rafiyath and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:21
  38. Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will ...

    Authors: Naomi Galili, Pablo Tamayo, Olga B Botvinnik, Jill P Mesirov, Margarita R Brooks, Gail Brown and Azra Raza
    Citation: Journal of Hematology & Oncology 2012 5:20
  39. Mesenchymal stem cells (MSC) have generated a great amount of enthusiasm over the past decade as a novel therapeutic paradigm for a variety of diseases. Currently, MSC based clinical trials have been conducted...

    Authors: Shihua Wang, Xuebin Qu and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2012 5:19
  40. Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells.

    Authors: Azra Raza, Naomi Galili, Deborah Mulford, Scott E Smith, Gail L Brown, David P Steensma, Roger M Lyons, Ralph Boccia, Mikkael A Sekeres, Guillermo Garcia-Manero and Ruben A Mesa
    Citation: Journal of Hematology & Oncology 2012 5:18
  41. Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant ...

    Authors: Eddy C Hsueh, Stephanie M Knebel, Wai-Hung Lo, Yun-Chung Leung, Paul Ning-Man Cheng and Chung-Tsen Hsueh
    Citation: Journal of Hematology & Oncology 2012 5:17

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here